Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anetumab Ravtansine in Mesothelin-Positive Lung Adenocarcinoma
NCT02839681Phase 2Terminated
- Sponsor
- National Cancer Institute
- Start
- Jul 2016
- Primary completion
- Jun 2018
- Modality
- Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
Phase 2, open-label trial of anetumab ravtansine in lung adenocarcinoma (2 arms), sponsored by National Cancer Institute. Primary endpoints: Recommended Phase 2 Dose at 21 days and Objective Response Rate at 6 weeks. Started Jul 2016; status: terminated.
02
Drugs
anetumab ravtansine
03
Conditions
lung adenocarcinoma
Beyond the preview
Go deeper on NCT02839681.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02839681.